$Supernus Pharmaceuticals (SUPN.US)$Revenue has grown in the...
$Supernus Pharmaceuticals (SUPN.US)$Revenue has grown in the past five years except for 2019, with an average growth rate of 17%. However, operating profit declined significantly in 2021 after increasing for three years, dropping by 54.7%, and continued to decline by 42.6% in 2022 mainly due to a sharp increase in operating expenses.
After checking the balance sheet, indeed in 2021, goodwill increased from 0.442 billion to 0.902 billion. This acquisition has greatly reduced the company's operational efficiency, and it has not recovered so far.
Revenue in Q1 2023 increased by 0.8%, and operating profit grew by 34% to 3.53 million from a very low base, while net income shrank by 34% due to a significant decline in interest income.
Currently, the pe ratio is 32.2, the pe ratio TTM is 37.2, lacking investment value before improving operational efficiency.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
